Innovative drug delivery platform relies on Telos Reagent Chips

Jeff Henise in the labTelos 2 Reagent Chips from Dolomite Microfluidics have helped San Francisco-based ProLynx to develop a novel drug delivery platform.

Jeff Henise, director of process development at ProLynx, explains: ‘Traditional polymer encapsulation delivery systems rely on diffusion or breakdown of the polymer to release their payload. In contrast, our drug delivery system offers controlled release using self-cleaving linkers to attach the drug to hydrogel microsphere carriers. Drug release and subsequent gel degradation depend only on the cleavage rate of the linker, and are tuneable across a wide range. A key part of our manufacturing process is the production of the hydrogel as microspheres, which is carried out using Telos 2 Reagent Chips.’

A customised approach

To produce microspheres of the correct size, ProLynx uses a microfluidics approach and a custom-made Telos chip with a 50 micrometre channel. This chip is robust, with excellent chemical compatibility, and offers a high throughput for its size.

Henise adds: ‘Although there are other ways of making emulsions, microfluidics offers better control of particle size and a high yield of monodisperse emulsion. As the resulting material does not need to be screened to remove incorrectly sized particles, this minimises waste and increases yield by as much as 30 percent.’


Subscribe to our mailing list

* indicates required

Would you like to receive our FREE e-newsletter?

* indicates required